The stock dipped 7.39 percent to Rs 732 on BSE. On NSE, it plunged 7.48 percent to Rs 731.

The warning letter follows inspection of the facility in September 2014 by US Food and Drug Administration (USFDA) inspectors.

''Sun Pharma expects to request a re-inspection by USFDA upon completion of its remediation commitments," the company had said in a statement on Saturday.

"Sun Pharma will respond to this warning letter with a detailed plan within the stipulated time frame," it said.

Latest News  from Business News Desk